Annual EBITDA
-$100.53 M
-$30.47 M-43.49%
31 December 2023
Summary:
Viking Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$100.53 million, with the most recent change of -$30.47 million (-43.49%) on 31 December 2023. During the last 3 years, it has fallen by -$58.15 million (-137.19%). VKTX annual EBITDA is now -82508.87% below its all-time high of -$121.70 thousand, reached on 31 December 2013.VKTX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$36.47 M
-$2.49 M-7.33%
30 September 2024
Summary:
Viking Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$36.47 million, with the most recent change of -$2.49 million (-7.33%) on 30 September 2024. Over the past year, it has dropped by -$9.28 million (-34.12%). VKTX quarterly EBITDA is now -2223.75% below its all-time high of $1.72 million, reached on 31 December 2014.VKTX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$133.66 M
-$9.28 M-7.46%
30 September 2024
Summary:
Viking Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$133.66 million, with the most recent change of -$9.28 million (-7.46%) on 30 September 2024. Over the past year, it has dropped by -$42.12 million (-46.02%). VKTX TTM EBITDA is now -121850.73% below its all-time high of -$109.60 thousand, reached on 31 December 2012.VKTX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VKTX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -43.5% | -34.1% | -46.0% |
| 3 y3 years | -137.2% | -173.6% | -146.8% |
| 5 y5 years | -364.2% | -394.6% | -363.1% |
VKTX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -137.2% | at low | -193.3% | at low | -146.8% | at low |
| 5 y | 5 years | -364.2% | at low | -394.6% | at low | -363.1% | at low |
| alltime | all time | <-9999.0% | at low | -2223.8% | at low | <-9999.0% | at low |
Viking Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$36.47 M(+7.3%) | -$133.66 M(+7.5%) |
| June 2024 | - | -$33.98 M(-0.1%) | -$124.38 M(+9.0%) |
| Mar 2024 | - | -$34.00 M(+16.4%) | -$114.07 M(+13.5%) |
| Dec 2023 | -$100.53 M(+43.5%) | -$29.21 M(+7.4%) | -$100.53 M(+9.8%) |
| Sept 2023 | - | -$27.19 M(+14.9%) | -$91.53 M(+13.9%) |
| June 2023 | - | -$23.67 M(+15.6%) | -$80.40 M(+8.1%) |
| Mar 2023 | - | -$20.46 M(+1.3%) | -$74.36 M(+6.1%) |
| Dec 2022 | -$70.06 M(+26.5%) | -$20.21 M(+25.9%) | -$70.06 M(+12.5%) |
| Sept 2022 | - | -$16.05 M(-8.9%) | -$62.29 M(+4.6%) |
| June 2022 | - | -$17.63 M(+9.0%) | -$59.56 M(+3.8%) |
| Mar 2022 | - | -$16.17 M(+30.0%) | -$57.40 M(+3.6%) |
| Dec 2021 | -$55.39 M(+30.7%) | -$12.43 M(-6.7%) | -$55.39 M(+2.3%) |
| Sept 2021 | - | -$13.33 M(-13.8%) | -$54.15 M(+7.0%) |
| June 2021 | - | -$15.47 M(+9.3%) | -$50.59 M(+13.4%) |
| Mar 2021 | - | -$14.16 M(+26.4%) | -$44.61 M(+7.9%) |
| Dec 2020 | -$42.38 M(+30.7%) | -$11.20 M(+14.6%) | -$41.33 M(+6.1%) |
| Sept 2020 | - | -$9.77 M(+3.0%) | -$38.94 M(+6.6%) |
| June 2020 | - | -$9.48 M(-12.8%) | -$36.54 M(-0.1%) |
| Mar 2020 | - | -$10.88 M(+23.5%) | -$36.56 M(+12.8%) |
| Dec 2019 | -$32.43 M(+49.7%) | -$8.81 M(+19.4%) | -$32.43 M(+12.4%) |
| Sept 2019 | - | -$7.37 M(-22.4%) | -$28.86 M(+2.8%) |
| June 2019 | - | -$9.51 M(+41.0%) | -$28.09 M(+11.9%) |
| Mar 2019 | - | -$6.74 M(+28.7%) | -$25.11 M(+15.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$21.66 M(+12.3%) | -$5.24 M(-20.6%) | -$21.66 M(+7.0%) |
| Sept 2018 | - | -$6.60 M(+1.1%) | -$20.25 M(+3.9%) |
| June 2018 | - | -$6.53 M(+98.2%) | -$19.49 M(+9.5%) |
| Mar 2018 | - | -$3.29 M(-14.0%) | -$17.80 M(-7.8%) |
| Dec 2017 | -$19.30 M(+49.3%) | -$3.83 M(-34.5%) | -$19.29 M(+3.3%) |
| Sept 2017 | - | -$5.84 M(+20.9%) | -$18.68 M(+15.2%) |
| June 2017 | - | -$4.83 M(+0.9%) | -$16.21 M(+11.5%) |
| Mar 2017 | - | -$4.79 M(+49.2%) | -$14.54 M(+12.5%) |
| Dec 2016 | -$12.92 M(-42.4%) | -$3.21 M(-4.9%) | -$12.92 M(-11.2%) |
| Sept 2016 | - | -$3.37 M(+6.6%) | -$14.55 M(-7.1%) |
| June 2016 | - | -$3.17 M(-0.2%) | -$15.66 M(-22.0%) |
| Mar 2016 | - | -$3.17 M(-34.4%) | -$20.09 M(-10.4%) |
| Dec 2015 | -$22.42 M(+5.5%) | -$4.84 M(+7.8%) | -$22.42 M(+41.3%) |
| Sept 2015 | - | -$4.49 M(-40.9%) | -$15.87 M(+38.9%) |
| June 2015 | - | -$7.59 M(+38.0%) | -$11.42 M(-57.0%) |
| Mar 2015 | - | -$5.50 M(-420.5%) | -$26.54 M(+24.9%) |
| Dec 2014 | -$21.26 M(>+9900.0%) | $1.72 M(-4382.3%) | -$21.26 M(-7.5%) |
| Sept 2014 | - | -$40.10 K(-99.8%) | -$22.97 M(+0.2%) |
| June 2014 | - | -$22.71 M(>+9900.0%) | -$22.93 M(+9576.2%) |
| Mar 2014 | - | -$220.00 K(+1194.1%) | -$237.00 K(+82.6%) |
| Dec 2013 | -$121.70 K | - | - |
| June 2013 | - | -$17.00 K(+431.3%) | -$129.80 K(+15.1%) |
| Mar 2013 | - | -$3200.00(-97.1%) | -$112.80 K(+2.9%) |
| Dec 2012 | - | -$109.60 K | -$109.60 K |
FAQ
- What is Viking Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Viking Therapeutics?
- What is Viking Therapeutics annual EBITDA year-on-year change?
- What is Viking Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Viking Therapeutics?
- What is Viking Therapeutics quarterly EBITDA year-on-year change?
- What is Viking Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Viking Therapeutics?
- What is Viking Therapeutics TTM EBITDA year-on-year change?
What is Viking Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of VKTX is -$100.53 M
What is the all time high annual EBITDA for Viking Therapeutics?
Viking Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$121.70 K
What is Viking Therapeutics annual EBITDA year-on-year change?
Over the past year, VKTX annual earnings before interest, taxes, depreciation & amortization has changed by -$30.47 M (-43.49%)
What is Viking Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of VKTX is -$36.47 M
What is the all time high quarterly EBITDA for Viking Therapeutics?
Viking Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $1.72 M
What is Viking Therapeutics quarterly EBITDA year-on-year change?
Over the past year, VKTX quarterly earnings before interest, taxes, depreciation & amortization has changed by -$9.28 M (-34.12%)
What is Viking Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of VKTX is -$133.66 M
What is the all time high TTM EBITDA for Viking Therapeutics?
Viking Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$109.60 K
What is Viking Therapeutics TTM EBITDA year-on-year change?
Over the past year, VKTX TTM earnings before interest, taxes, depreciation & amortization has changed by -$42.12 M (-46.02%)